Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VTGN - Vistagen Therapeutics Inc.


IEX Last Trade
3.49
-0.030   -0.860%

Share volume: 45,027
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.52
-0.03
-0.85%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
28%
Profitability 43%
Dept financing 25%
Liquidity 25%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
-4.90%
1 Month
-1.13%
3 Months
-10.28%
6 Months
-33.01%
1 Year
-34.77%
2 Year
-33.45%
Key data
Stock price
$3.49
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.45 - $7.35
52 WEEK CHANGE
-$0.41
MARKET CAP 
94.422 M
YIELD 
N/A
SHARES OUTSTANDING 
27.055 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
1.38
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$94,372
AVERAGE 30 VOLUME 
$102,022
Company detail
CEO:
Region: US
Website: vistagen.com
Employees: 33
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.

Recent news